Ulrich von Grünhagen

Author

Praxis für Hämatologie und Onkologie

Also Known As

G. Schott, U VON GRÜNHAGEN, U von Grünhagen, U. von Grünhagen, Ulrich von Grünhagen, Ulrich von Grünhagen

Publications

3.9K

Citations

H-Index

Concepts

All Affiliations

Praxis für Hämatologie und Onkologie Goethe University Frankfurt Krankenhaus Nordwest Medizinische Hochschule Hannover University Hospital Frankfurt

About

Ulrich von Grünhagen is an author at Praxis für Hämatologie und Onkologie specializing in oncology, medicine, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	3.4K
2	Health Sciences	4	4	3.4K
3	Immunology	3	3	1.9K
4	Pathology	3	3	1.5K
5	Pharmacology	1	1	44

Ulrich von Grünhagen

Publications

3.9K

Citations

H-Index

Page 1

	Year	Citations
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial Michael Hallek, Kirsten Fischer, Guenter Fingerle-Rowson, The Lancet Hematological MalignancyLymphoid NeoplasiaOncologyChronic Lymphocytic LeukaemiaImmunology	2010	1.9K
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial Mathias Rummel, N. Niederle, Georg Maschmeyer, The Lancet Lymphoid NeoplasiaRituximab Versus ChopOncologyMantle-cell LymphomasMetronomic Therapy	2013	1.5K
Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma Mathias Rummel, S. Al-Batran, Soo-Z. Kim, Journal of Clinical Oncology	2005	439
Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma Mathias Rummel, Kai Uwe Chow, T. Karakas, European Journal of Cancer Lymphoid NeoplasiaOncologyMedicinePharmacotherapyMetronomic Chemotherapy	2002	44
Efficacy and Tolerability of Alemtuzumab (CAMPATH-1H) in the Salvage Treatment of B-Cell Chronic Lymphocytic Leukemia—Change of Regimen Needed? Kathrin Rieger, Ulrich von Grünhagen, Thomas Fietz, Leukemia & lymphoma/Leukemia and lymphoma Mixed-phenotype Acute LeukemiaRegimen NeededImmunologyPathologyPharmacotherapy	2003	30
FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia Nadine Kutsch, Raymonde Busch, Jasmin Bahlo, Leukemia & lymphoma/Leukemia and lymphoma Quality Of LifeChronic Lymphocytic LeukemiaMixed-phenotype Acute LeukemiaImmunologyPathology	2016	17
Bendamustine Plus Rituximab (B-R) Versus CHOP Plus Rituximab (CHOP-R) As First-Line Treatment in Patients with Indolent and Mantle Cell Lymphomas (MCL) – 7 Year Updated Results from the StiL NHL1 Study Mathias Rummel, Georg Maschmeyer, Arnold Ganser, Blood	2014	13

Page 1